Galena Biopharma (GALE) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
Roth Cap Remains Positive on Galena Biopharma (GALE) Following Q3 Results, Update
November 4, 2014 11:56 AM ESTRoth Capital affirms Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $8 following Q3 results.
Analyst Joseph Pantginis noted that Galena's loss of $0.05 per share compared with the firm's loss estimate of $0.18 per share and the consensus loss of $0.11 per share. The analyst noted that, Revenue, based on Abstral sales came in at $1.62 million compared with our estimate of $2.34 million and the consensus estimate of $2.66 million and the company reiterated... More
